ZIB

Electronic Resource

Steroid sulfatase activities in normal and cirrhotic livers and plasma levels of estrone sulfate, estrone and estradiol-17β in men

Prost, O. ; Ottignon, Y. ; Remy-Martin, A. ; [et al.]

Amsterdam : Elsevier

Steroids 43 (1984), S. 189-199

add to mindlist on the mindlist

Details

ISSN: 0039-128X

Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Topics: Medicine

Type of Medium: Electronic Resource

URL: http://linkinghub.elsevier.com/retrieve/pii/0039-128X(84)90037-0

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Is the management of hepatitis C patients appropriate? A population-based study (2005)

Hatem, C. ; Minello, A. ; Bresson-Hadni, S. ; [et al.]

Oxford, UK : Blackwell Science Ltd

Alimentary pharmacology & therapeutics 21 (2005), S. 0

add to mindlist on the mindlist

Details

ISSN: 1365-2036

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: Background : In order for hepatitis C patients to receive antiviral treatment, they must reach medical care.Aim : To assess the proportion of patients reaching medical care after hepatitis C diagnosis in a general population (1 006 171 inhabitants) in France.Methods : Between 1994 and 1999, 1508 cases were diagnosed, of which 1251 were eligible for the study.Results : Two-hundred and two patients did not have any medical care; among them, 55.4% had normal alanine transferase, 58.4% had risk factors related to lifestyle and 22.8% were alcoholics. Amongst the 1049 other patients, 41.6% had a liver biopsy, 25.0% were treated. Treatment was more often carried out in males than in females (OR: 1.59; P = 0.001), and in patients under 65 than in older patients (OR: 2.22; P 〈 0.008). Among non-treatment reasons, alcoholism (P = 0.001), drug-addiction (P = 0.04) and escaping monitoring (P = 0.04) were more frequent in males than in females, whereas normal alanine transferase was more frequent in females than in males (P = 0.004). Amongst 278 patients with a Metavir score 〉A1F1, 71 (25.5%) did not undergo treatment.Conclusion : In a general population, one patient in six did not receive on-going health care; a quarter of patients with a Metavir score 〉A1F1 did not receive any treatment. These results showed insufficient clinical management, which could compromise the effectiveness of treatment in general population.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1111/j.1365-2036.2005.02393.x

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients (1996)

Maboundou, C. W. ; Paintaud, G. ; Vanlemmens, C. ; [et al.]

Springer

European journal of clinical pharmacology 50 (1996), S. 335-337

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: Key words Cyclosporine ; Ursodiol; ursodeoxycholic acid ; absorption ; pharmacokinetics ; liver transplantation

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Abstract Objective: To study the possible influence of ursodiol (ursodeoxycholic acid), a hydrophilic bile acid, on cyclosporine (CsA) bioavailability. Methods: Seven adult liver transplant recipients participated in a randomised cross-over pharmacokinetic study comparing ursodiol (600 mg) with placebo in single doses. Blood concentrations of CsA were measured by HPLC. Results: There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng⋅h⋅ml–1, Cmax was 832 vs 871 ng⋅ml–1 and tmax was 2 vs 2 h, after ursodiol and placebo, respectively. Conclusion: Although a significant period effect was observed, we conclude that a single dose of ursodiol has little effect on CsA absorption in liver transplant patients and that an interaction in the intestinal lumen between these two drugs is unlikely.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/s002280050118

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4 (1998)

Monek, O. ; Paintaud, G. ; Bechtel, Y. ; [et al.]

Springer

European journal of clinical pharmacology 54 (1998), S. 47-52

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: Key words CYP2D6 ; Liver transplantation

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Abstract Objective: After liver transplantation (LT), genotypic differences between the recipient and the transplanted liver, medications and post-LT complications may all affect drug metabolism. We have studied the effect of two CYP2D6 mutations in the donor and the recipient on post-LT CYP2D6 phenotype. Method: The CYP2D6 phenotype was assessed in 48 patients before and after LT with debrisoquine or␣dextromethorphan. CYP2D6*3 (CYP2D6A) and CYP2D6*4 (CYP2D6B) mutations were detected in the donor and the recipient using polymerase chain reaction. Results: Before LT, 40 subjects were classified as extensive metabolisers (EM) and 8 as poor metabolisers (PM); after transplantation, 41 were EMs and 7 were PMs. Genotype and phenotype were in agreement in 100% of EMs and 40% of PMs. The low percentage of agreement in PMs could not be explained by severely altered liver function. The phenotype of 13 subjects was apparently changed by LT: 6 EMs became PMs and 7 PMs became EMs. All four subjects in whom genotype changed following LT had a corresponding change in phenotype: two EM subjects became PMs and two PM subjects became EMs. Conclusion: The low percentage of agreement in PMs may be partly explained by mutations other than CYP2D6*3 and CYP2D6*4. Nevertheless, our study shows that the CYP2D6 genotype of the donor controls the phenotype of the recipient of a liver transplantation.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/s002280050419

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Cholestasis and hepatic drug metabolism (1981)

Miguet, J. -P. ; Vuitton, Dominique ; Deschamps, J. -P. ; [et al.]

Springer

Digestive diseases and sciences 26 (1981), S. 718-722

add to mindlist on the mindlist

Details

ISSN: 1573-2568

Source: Springer Online Journal Archives 1860-2000

Topics: Medicine

Notes: Abstract The antipyrine metabolic clearance rate (MCR) was studied in two groups of patients with similar degrees of cholestasis and hepatic damage, but differing mechanisms of cholestasis. The plasma disappearance rate of antipyrine in 18 patients with extrahepatic cholestasis and 11 patients with intrahepatic cholestasis was compared with that of two groups of control subjects without liver disease who were matched for age. Whereas no significant difference was observed for the antipyrine MCR between patients with extrahepatic cholestasis and their controls [30.7±11.2 (sd) as against 31.6±10.0 ml/min], the antipyrine MCR was significantly lower (P〈0.001) in the patients with intrahepatic cholestasis than in their controls (16.2±4.5 vs 37.4±17.3 ml/min). These results suggest that cholestasisper se does not change the rate of metabolism of drugs by the liver. The decrease of antipyrine MCR in patients with intrahepatic cholestasis could be due to a reduced functional parenchymal mass related to some degree of hepatic necrosis.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/BF01316861

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

hits 1 - 5 | 5 hits